NasdaqGS:APLSBiotechs
Apellis Adds Ex Pfizer R&D Chief To Board As Growth Plans Evolve
Apellis Pharmaceuticals (NasdaqGS:APLS) has appointed Dr. Mikael Dolsten to its board of directors.
Dr. Dolsten is a former chief scientific officer at Pfizer with extensive experience in pharmaceutical R&D and drug approvals.
The appointment adds long tenured large pharma leadership to Apellis' governance and scientific oversight.
Apellis focuses on therapies that target the complement system, a part of the immune system that plays a role in several serious diseases. For investors watching...